QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Doug Lakin who started this subject	4/25/2001 5:51:54 PM
From: Ian@SI	of 1321

Nice report and conference call tonight. No new data presented but will be at ARVO Apr 29th to May 4th in Fort Lauderdale. During the Q&A, Julia dropped a couple hints about how good the data will be. During one Answer on Retreatment rates, she advised that some patients may have the leakage stopped with less than 3 treatments, others take more. Then she added that she believes that the data presented at ARVO will bear that out. Sounds like we'll see some very significant differences in Vision after the 3rd year for those treated vs the placebos. A similar "hint" came on another topic which has completely disappeared from my short term memory. :-( Replay available through the web site: qltinc.com or at streetevents.com By phone at 416 626 4100 Passcode: 1847 8353#

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next